Latest News-EVEREST MEDICINES Mediaroom_Page

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines

2022-01-04 08:00 3596

Everest Medicines and Providence Therapeutics announces that PTX-COVID19-B, a mRNA Vaccine for COVID-19, has received approval for inclusion in WHO Solidarity Trial Vaccines (STV) Program

SHANGHAI, Dec. 20, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) and Providence Therapeutic...

2021-12-20 20:55 3631

Everest Medicines announces FDA grants our Partner Calliditas Therapeutics Accelerated Approval of TARPEYO™ (budesonide) to Reduce Proteinuria in IgA Nephropathy

* TARPEYO (budesonide) delayed release capsules is the first and only treatment indicated to redu...

2021-12-16 08:49 3253

Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea

SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- Everest Medicines

2021-12-15 08:00 3307

Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant

SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therape...

2021-12-01 08:00 2431

Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index

SHANGHAI, Nov. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"...

2021-11-24 08:00 2023

Everest Medicines Announces Inclusion in the MSCI Global Small Cap Indexes - MSCI China Index

SHANGHAI, Nov. 24, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"...

2021-11-24 08:00 2645

Everest Medicines and Gilead Sciences Jointly Announce Phase 2b Study of Sacituzumab Govitecan Conducted in China of Patients With Metastatic Triple-negative Breast Cancer Meets Primary Overall Response Rate Endpoint

SHANGHAI, Nov. 11, 2021 /PRNewswire/ -- Everest Medicines and Gilead Sciences, Inc. (Nasdaq: GILD)...

2021-11-11 08:05 3291

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company...

2021-11-08 08:15 2663

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company...

2021-11-08 08:10 1854

Everest Medicines Announces Share Repurchase Transaction Details

SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company")...

2021-11-01 08:00 2185

Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, Sept. 29, 2021 /PRNewswire/ -- Everest Medicines

2021-09-29 17:44 2859

Everest Medicines Announces Approval of Investigational New Drug Application by China NMPA for SPR206

SHANGHAI, Sept. 24, 2021 /PRNewswire/ -- Everest Medicines

2021-09-24 13:56 3511

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

VANCOUVER, British Columbia and SHANGHAI, Sept. 23, 2021 /PRNewswire/ -- AbCellera

2021-09-23 06:00 3300

Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases

SHANGHAI, Sept. 17, 2021 /PRNewswire/ -- Everest Medicines

2021-09-17 06:30 5581

Everest Medicines Enters into Comprehensive Agreements with Providence Therapeutics to Advance mRNA Vaccines and Therapies, including COVID-19 Vaccines, in Asia Emerging Markets

SHANGHAI, Sept. 13, 2021 /PRNewswire/ -- Everest Medicines Limited

2021-09-13 17:00 4240

Everest Medicines Announces Half-Year 2021 Interim Results

SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines

2021-08-30 22:15 3965

Everest Medicines Announces Up to HK$100 million Share Repurchase Program

SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical compa...

2021-08-30 22:03 3431

Everest Medicines Announces First Person Dosed in Global Phase 3 Registration Trial of Sacituzumab Govitecan-Hziy in China for Metastatic Urothelial Cancer

SHANGHAI, Aug. 26, 2021 /PRNewswire/ -- Everest Medicines

2021-08-26 21:40 4746

Everest Medicines to Announce Half-Year 2021 Interim Results

SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical compa...

2021-08-23 15:20 3238